AU2017200029B2 - Methods of determining amyloid beta turnover in blood - Google Patents
Methods of determining amyloid beta turnover in blood Download PDFInfo
- Publication number
- AU2017200029B2 AU2017200029B2 AU2017200029A AU2017200029A AU2017200029B2 AU 2017200029 B2 AU2017200029 B2 AU 2017200029B2 AU 2017200029 A AU2017200029 A AU 2017200029A AU 2017200029 A AU2017200029 A AU 2017200029A AU 2017200029 B2 AU2017200029 B2 AU 2017200029B2
- Authority
- AU
- Australia
- Prior art keywords
- amount
- val
- gly
- labelled
- labeled
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000008280 blood Substances 0.000 title claims abstract description 89
- 210000004369 blood Anatomy 0.000 title claims abstract description 89
- 238000000034 method Methods 0.000 title claims abstract description 47
- 230000007306 turnover Effects 0.000 title claims abstract description 33
- 102000013455 Amyloid beta-Peptides Human genes 0.000 title claims abstract description 10
- 108010090849 Amyloid beta-Peptides Proteins 0.000 title claims abstract description 10
- 150000001413 amino acids Chemical class 0.000 claims abstract description 44
- 238000001802 infusion Methods 0.000 claims abstract description 15
- 230000002285 radioactive effect Effects 0.000 claims abstract description 14
- 238000001990 intravenous administration Methods 0.000 claims abstract description 9
- 238000004949 mass spectrometry Methods 0.000 claims abstract description 7
- 238000001727 in vivo Methods 0.000 claims abstract description 6
- 238000000338 in vitro Methods 0.000 claims abstract description 3
- 241000282414 Homo sapiens Species 0.000 claims description 7
- 108010065395 Neuropep-1 Proteins 0.000 claims 4
- 101100512078 Caenorhabditis elegans lys-1 gene Proteins 0.000 claims 3
- 108010008685 alanyl-glutamyl-aspartic acid Proteins 0.000 claims 3
- XWKPSMRPIKKDDU-RCOVLWMOSA-N Asp-Val-Gly Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(O)=O XWKPSMRPIKKDDU-RCOVLWMOSA-N 0.000 claims 2
- KJBGAZSLZAQDPV-KKUMJFAQSA-N Glu-Phe-Arg Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)NC(=O)[C@H](CCC(=O)O)N KJBGAZSLZAQDPV-KKUMJFAQSA-N 0.000 claims 2
- ZALGPUWUVHOGAE-GVXVVHGQSA-N Glu-Val-His Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)NC(=O)[C@H](CCC(=O)O)N ZALGPUWUVHOGAE-GVXVVHGQSA-N 0.000 claims 2
- YMUFWNJHVPQNQD-ZKWXMUAHSA-N Gly-Ala-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)CN YMUFWNJHVPQNQD-ZKWXMUAHSA-N 0.000 claims 2
- YSDLIYZLOTZZNP-UWVGGRQHSA-N Gly-Leu-Met Chemical compound CSCC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)CN YSDLIYZLOTZZNP-UWVGGRQHSA-N 0.000 claims 2
- VPZXBVLAVMBEQI-VKHMYHEASA-N Glycyl-alanine Chemical compound OC(=O)[C@H](C)NC(=O)CN VPZXBVLAVMBEQI-VKHMYHEASA-N 0.000 claims 2
- NWGXCPUKPVISSJ-AVGNSLFASA-N His-Gln-Lys Chemical compound C1=C(NC=N1)C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCCCN)C(=O)O)N NWGXCPUKPVISSJ-AVGNSLFASA-N 0.000 claims 2
- XOEDPXDZJHBQIX-ULQDDVLXSA-N Leu-Val-Phe Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 XOEDPXDZJHBQIX-ULQDDVLXSA-N 0.000 claims 2
- 108010079364 N-glycylalanine Proteins 0.000 claims 2
- CYZBFPYMSJGBRL-DRZSPHRISA-N Phe-Ala-Glu Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(O)=O CYZBFPYMSJGBRL-DRZSPHRISA-N 0.000 claims 2
- VGNYHOBZJKWRGI-CIUDSAMLSA-N Ser-Asn-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](N)CO VGNYHOBZJKWRGI-CIUDSAMLSA-N 0.000 claims 2
- OQPNSDWGAMFJNU-QWRGUYRKSA-N Ser-Gly-Tyr Chemical compound OC[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 OQPNSDWGAMFJNU-QWRGUYRKSA-N 0.000 claims 2
- PIFJAFRUVWZRKR-QMMMGPOBSA-N Val-Gly-Gly Chemical compound CC(C)[C@H]([NH3+])C(=O)NCC(=O)NCC([O-])=O PIFJAFRUVWZRKR-QMMMGPOBSA-N 0.000 claims 2
- VPZXBVLAVMBEQI-UHFFFAOYSA-N glycyl-DL-alpha-alanine Natural products OC(=O)C(C)NC(=O)CN VPZXBVLAVMBEQI-UHFFFAOYSA-N 0.000 claims 2
- 108010050848 glycylleucine Proteins 0.000 claims 2
- 108010037850 glycylvaline Proteins 0.000 claims 2
- 108010028295 histidylhistidine Proteins 0.000 claims 2
- 108010064235 lysylglycine Proteins 0.000 claims 2
- 108010073025 phenylalanylphenylalanine Proteins 0.000 claims 2
- XEDQMTWEYFBOIK-ACZMJKKPSA-N Asp-Ala-Glu Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(O)=O XEDQMTWEYFBOIK-ACZMJKKPSA-N 0.000 claims 1
- 101100289888 Caenorhabditis elegans lys-5 gene Proteins 0.000 claims 1
- WATXSTJXNBOHKD-LAEOZQHASA-N Glu-Asp-Val Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(O)=O WATXSTJXNBOHKD-LAEOZQHASA-N 0.000 claims 1
- OLPPXYMMIARYAL-QMMMGPOBSA-N Gly-Gly-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)CNC(=O)CN OLPPXYMMIARYAL-QMMMGPOBSA-N 0.000 claims 1
- DKEXFJVMVGETOO-LURJTMIESA-N Gly-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)CN DKEXFJVMVGETOO-LURJTMIESA-N 0.000 claims 1
- IALQAMYQJBZNSK-WHFBIAKZSA-N Gly-Ser-Asn Chemical compound [H]NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(O)=O IALQAMYQJBZNSK-WHFBIAKZSA-N 0.000 claims 1
- UVTSZKIATYSKIR-RYUDHWBXSA-N Gly-Tyr-Glu Chemical compound [H]NCC(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O UVTSZKIATYSKIR-RYUDHWBXSA-N 0.000 claims 1
- KSOBNUBCYHGUKH-UWVGGRQHSA-N Gly-Val-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)CN KSOBNUBCYHGUKH-UWVGGRQHSA-N 0.000 claims 1
- MDCTVRUPVLZSPG-BQBZGAKWSA-N His-Asp Chemical compound OC(=O)C[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CNC=N1 MDCTVRUPVLZSPG-BQBZGAKWSA-N 0.000 claims 1
- ZZLWLWSUIBSMNP-CIUDSAMLSA-N His-Asp-Ser Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O ZZLWLWSUIBSMNP-CIUDSAMLSA-N 0.000 claims 1
- YNMQUIVKEFRCPH-QSFUFRPTSA-N Ile-Ile-Gly Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)O)N YNMQUIVKEFRCPH-QSFUFRPTSA-N 0.000 claims 1
- NJMXCOOEFLMZSR-AVGNSLFASA-N Leu-Met-Val Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(O)=O NJMXCOOEFLMZSR-AVGNSLFASA-N 0.000 claims 1
- CQRGINSEMFBACV-WPRPVWTQSA-N Met-Val-Gly Chemical compound CSCC[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)NCC(O)=O CQRGINSEMFBACV-WPRPVWTQSA-N 0.000 claims 1
- SITLTJHOQZFJGG-UHFFFAOYSA-N N-L-alpha-glutamyl-L-valine Natural products CC(C)C(C(O)=O)NC(=O)C(N)CCC(O)=O SITLTJHOQZFJGG-UHFFFAOYSA-N 0.000 claims 1
- XMBSYZWANAQXEV-UHFFFAOYSA-N N-alpha-L-glutamyl-L-phenylalanine Natural products OC(=O)CCC(N)C(=O)NC(C(O)=O)CC1=CC=CC=C1 XMBSYZWANAQXEV-UHFFFAOYSA-N 0.000 claims 1
- MQWISMJKHOUEMW-ULQDDVLXSA-N Phe-Arg-His Chemical compound C([C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC=1NC=NC=1)C(O)=O)C1=CC=CC=C1 MQWISMJKHOUEMW-ULQDDVLXSA-N 0.000 claims 1
- JKJSIYKSGIDHPM-WBAXXEDZSA-N Phe-Phe-Ala Chemical compound C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](N)Cc1ccccc1)C(O)=O JKJSIYKSGIDHPM-WBAXXEDZSA-N 0.000 claims 1
- DHINLYMWMXQGMQ-IHRRRGAJSA-N Val-His-His Chemical compound C([C@H](NC(=O)[C@@H](N)C(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(O)=O)C1=CN=CN1 DHINLYMWMXQGMQ-IHRRRGAJSA-N 0.000 claims 1
- CPGJELLYDQEDRK-NAKRPEOUSA-N Val-Ile-Ala Chemical compound CC[C@H](C)[C@H](NC(=O)[C@@H](N)C(C)C)C(=O)N[C@@H](C)C(O)=O CPGJELLYDQEDRK-NAKRPEOUSA-N 0.000 claims 1
- WBPFYNYTYASCQP-CYDGBPFRSA-N Val-Val-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)N WBPFYNYTYASCQP-CYDGBPFRSA-N 0.000 claims 1
- 229940024606 amino acid Drugs 0.000 description 34
- 235000001014 amino acid Nutrition 0.000 description 34
- 108090000765 processed proteins & peptides Proteins 0.000 description 15
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 12
- 239000011324 bead Substances 0.000 description 12
- 230000004060 metabolic process Effects 0.000 description 12
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 10
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 9
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 9
- 210000003169 central nervous system Anatomy 0.000 description 8
- 102000004196 processed proteins & peptides Human genes 0.000 description 8
- 150000002500 ions Chemical class 0.000 description 7
- 235000018102 proteins Nutrition 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 208000024827 Alzheimer disease Diseases 0.000 description 6
- 239000004475 Arginine Substances 0.000 description 6
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 6
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 6
- 239000004471 Glycine Substances 0.000 description 6
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 6
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 6
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 6
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 6
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 6
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 6
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 6
- 239000004472 Lysine Substances 0.000 description 6
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 6
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 6
- 235000009697 arginine Nutrition 0.000 description 6
- 235000009582 asparagine Nutrition 0.000 description 6
- 229960001230 asparagine Drugs 0.000 description 6
- 235000003704 aspartic acid Nutrition 0.000 description 6
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 6
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 6
- 235000018417 cysteine Nutrition 0.000 description 6
- 238000001514 detection method Methods 0.000 description 6
- 235000013922 glutamic acid Nutrition 0.000 description 6
- 239000004220 glutamic acid Substances 0.000 description 6
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 6
- 235000004554 glutamine Nutrition 0.000 description 6
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 6
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 6
- 229960000310 isoleucine Drugs 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 229930182817 methionine Natural products 0.000 description 6
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 6
- 239000004474 valine Substances 0.000 description 6
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 5
- 102000001708 Protein Isoforms Human genes 0.000 description 5
- 108010029485 Protein Isoforms Proteins 0.000 description 5
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 5
- 239000004473 Threonine Substances 0.000 description 5
- 102000004142 Trypsin Human genes 0.000 description 5
- 108090000631 Trypsin Proteins 0.000 description 5
- 235000019253 formic acid Nutrition 0.000 description 5
- 239000012634 fragment Substances 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 238000002552 multiple reaction monitoring Methods 0.000 description 5
- 210000002381 plasma Anatomy 0.000 description 5
- 239000012588 trypsin Substances 0.000 description 5
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 4
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 4
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 4
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 4
- 235000004279 alanine Nutrition 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000003797 essential amino acid Substances 0.000 description 4
- 235000020776 essential amino acid Nutrition 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000002372 labelling Methods 0.000 description 4
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 4
- 238000011002 quantification Methods 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 3
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 3
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 238000001114 immunoprecipitation Methods 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 230000032258 transport Effects 0.000 description 3
- 108091005804 Peptidases Proteins 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 238000013467 fragmentation Methods 0.000 description 2
- 238000006062 fragmentation reaction Methods 0.000 description 2
- 229960000789 guanidine hydrochloride Drugs 0.000 description 2
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 2
- 238000001948 isotopic labelling Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000007310 pathophysiology Effects 0.000 description 2
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 2
- 230000035479 physiological effects, processes and functions Effects 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- AOVFBIOEVVGLBW-NYWHIHTDSA-N (2S)-2-amino-3-hydroxypropanoic acid (2S)-pyrrolidine-2-carboxylic acid Chemical compound OC[C@H](N)C(O)=O.OC[C@H](N)C(O)=O.OC(=O)[C@@H]1CCCN1 AOVFBIOEVVGLBW-NYWHIHTDSA-N 0.000 description 1
- FBVVGPMIPAZFAW-RZVRUWJTSA-N (2S)-pyrrolidine-2-carboxylic acid Chemical compound OC(=O)[C@@H]1CCCN1.OC(=O)[C@@H]1CCCN1 FBVVGPMIPAZFAW-RZVRUWJTSA-N 0.000 description 1
- KUNFMZSTKSLIEY-GRHHLOCNSA-N (2s)-2-azanyl-3-phenyl-propanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1.OC(=O)[C@@H](N)CC1=CC=CC=C1 KUNFMZSTKSLIEY-GRHHLOCNSA-N 0.000 description 1
- YUXKOWPNKJSTPQ-AXWWPMSFSA-N (2s,3r)-2-amino-3-hydroxybutanoic acid;(2s)-2-amino-3-hydroxypropanoic acid Chemical compound OC[C@H](N)C(O)=O.C[C@@H](O)[C@H](N)C(O)=O YUXKOWPNKJSTPQ-AXWWPMSFSA-N 0.000 description 1
- 238000004780 2D liquid chromatography Methods 0.000 description 1
- DEFJQIDDEAULHB-UHFFFAOYSA-N Alanyl-alanine Chemical compound CC(N)C(=O)NC(C)C(O)=O DEFJQIDDEAULHB-UHFFFAOYSA-N 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 208000037259 Amyloid Plaque Diseases 0.000 description 1
- 241000512259 Ascophyllum nodosum Species 0.000 description 1
- 241001474374 Blennius Species 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- 101710118538 Protease Proteins 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- FEWOUVRMGWFWIH-ILZZQXMPSA-N amyloid-beta polypeptide 40 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 FEWOUVRMGWFWIH-ILZZQXMPSA-N 0.000 description 1
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 150000001540 azides Chemical class 0.000 description 1
- 239000012503 blood component Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000011210 chromatographic step Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000012001 immunoprecipitation mass spectrometry Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 231100000863 loss of memory Toxicity 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000004898 n-terminal fragment Anatomy 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 108010045269 tryptophyltryptophan Proteins 0.000 description 1
Landscapes
- Investigating Or Analysing Biological Materials (AREA)
Abstract
The invention is directed to an in vitro method for measuring the in vivo rate of amyloid beta (A3 ) turnover in the blood of a subject comprising: (a) determining by mass spectrometry the amount of labelled AP, or the amount of labelled A3 and unlabelled AP, in a blood sample obtained from the subject, (b) calculating the rate of AP clearance using the amount of labelled A, or the amount of labelled A3 and the amount of unlabelled A3, determined in step (a), wherein (i) the rate of AP clearance is calculated from the amount of labelled A, or the amount of labelled A3 and the amount of unlabelled A, in a sample obtained between 10 hours and 20 hours after intravenous administration by a 9 hour infusion has begun of at least one amino acid labelled with a stable non radioactive isotope to the subject, or (ii) the rate of AP clearance is calculated from the amount of labelled AP, or the amount of labelled A3 and the amount of unlabelled AI, in a sample obtained after 4, 5, 6, 7, 8, 9, or 10 hours after oral or intravenous bolus administration of at least one amino acid labelled with a stable non-radioactive isotope to the subject.
Description
The invention is directed to an in vitro method for measuring the in vivo rate of amyloid beta (Αβ ) turnover in the blood of a subject comprising:
(a) determining by mass spectrometry the amount of labelled Αβ, or the amount of labelled Αβ and unlabelled Αβ, in a blood sample obtained from the subject, (b) calculating the rate of Αβ clearance using the amount of labelled Αβ, or the amount of labelled Αβ and the amount of unlabelled Αβ, determined in step (a), wherein (i) the rate of Αβ clearance is calculated from the amount of labelled Αβ, or the amount of labelled Αβ and the amount of unlabelled Αβ, in a sample obtained between 10 hours and 20 hours after intravenous administration by a 9 hour infusion has begun of at least one amino acid labelled with a stable nonradioactive isotope to the subject, or (ii) the rate of Αβ clearance is calculated from the amount of labelled Αβ, or the amount of labelled Αβ and the amount of unlabelled Αβ, in a sample obtained after 4, 5, 6, 7, 8, 9, or 10 hours after oral or intravenous bolus administration of at least one amino acid labelled with a stable non-radioactive isotope to the subject.
WO 2011/149947
PCT/US2011/037754
2017200029 04 Jan 2017
METHODS OF DETERMINING AMYLOID BETA TURNOVER IN BLOOD
GOVERNMENTAL RIGHTS [0001] This invention was made with government support under K-23AG03094601 and R-01-NS065667 awarded by the National Institutes of Health. The government has certain rights in the invention.
REFERENCE TO SEQUENCE LISTING [0002] A paper copy of the sequence listing and a computer readable form of the same sequence listing are appended below and herein incorporated by reference. The information recorded in computer readable form is identical to the written sequence listing, according to 37 C.F.R. 1.821 (f).
FIELD OF THE INVENTION [0003] The invention encompasses a method for determining Αβ metabolism in blood.
BACKGROUND OF THE INVENTION [0004] Alzheimer disease (AD) is the most common cause of dementia and is an increasing public health problem. It is currently estimated to afflict 5 million people in the United States, with an expected increase to 13 million by the year 2050. AD leads to loss of memory, cognitive function, and ultimately independence. AD takes a heavy personal and financial toll on the patient and the family. Because of the severity and increasing prevalence of the disease in the population, it is urgent that better treatments be developed and delivered at the earliest stage of the disease.
WO 2011/149947
PCT/US2011/037754
2017200029 04 Jan 2017
REFERENCE TO COLOR FIGURES [0005] The application file contains at least one photograph executed in color. Copies of this patent application publication with color photographs will be provided by the Office upon request and payment of the necessary fee.
BRIEF DESCRIPTION OF THE FIGURES [0006] FIG. 1 depicts a graph showing the percent labeled total Αβ in blood over 36 to 48 hours for 6 participants (blue circles) and percent labeled total Αβ in CSF in twelve participants (red squares). Note the rapid rise to plateau by 9 hours with a rapid clearance rate in blood, while CSF does not approach plateau until 18 hours or later. Also note the much more rapid clearance of blood Αβ compared to CSF Αβ. There also may be a second peak of labeled Αβ in blood from 20 to 30 hours (peak ~26 hours).
[0007] FIG. 2 depicts percent labeled Αβ in blood over 40 hours after (a) intravenous labeling and (b) oral labeling.
[0008] FIG. 3 depicts absolute quantitation of blood Αβ isoforms over 40 hours. Labeled N15 Amyloid-beta internal standards (ISTD) were added to the sample before processing. Samples were processed as described in the examples, and absolute amounts of amyloid beta isoforms are plotted.
DETAILED DESCRIPTION OF THE INVENTION [0009] The present invention provides a method for determining Αβ metabolism by measuring Αβ turnover in a blood sample. As used herein, “turnover” refers in one embodiment to the rate of labeled Αβ production, the rate of labeled Αβ clearance, or a combination of both, as detailed below. In each instance, however, determining Αβ metabolism requires a measurement of labeled Αβ in a sample. In another embodiment, “turnover” refers to the half-life of Αβ in blood. As used herein, “Αβ” refers to total amyloidβ, an amyloidβ isoform such as Αβ38, Αβ40, or Αβ42, or a combination thereof. Advantageously, a method
WO 2011/149947
PCT/US2011/037754
2017200029 04 Jan 2017 of the invention eliminates the need for a more difficult to obtain and invasive central nervous system sample to determine the metabolism of Αβ.
I. Method for determining Αβ metabolism in blood [0010] One aspect of the present invention is a method for determining Αβ metabolism in blood. Importantly, the turnover of Αβ in blood may reflect the metabolism of Αβ in the central nervous system. (This is contrary to steady-state blood Αβ levels, which have not been successfully correlated to central nervous system Αβ.) Generally speaking, measuring the turnover of Αβ in blood comprises administering a label to a subject, collecting a blood sample from the subject, and analyzing the sample to determine the turnover of Αβ in the sample. Each step is described in more detail below.
(a) administering a label [0011] A method of the invention comprises, in part, administering a label to a subject. Suitable labels and suitable methods of administration are detailed below.
/'. labels [0012] Suitable labels should allow the measurement of the turnover of Αβ in the blood. By way of non-limiting example, a suitable label may include a labeled amino acid or a labeled amino acid precursor. In one embodiment, the label may comprise at least one labeled amino acid. The amino acid may be naturally occurring, synthetic, or an amino acid analogue. In each instance, however, the amino acid should be capable of incorporation into Αβ to allow detection and quantification of the turnover of Αβ in blood. Non-limiting examples of natural amino acids may include alanine, arginine, asparagine, aspartic acid, cysteine, glutamic acid, glutamine, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, or valine. In one embodiment, the amino acid may be an essential amino acid (e.g.,
WO 2011/149947
PCT/US2011/037754
2017200029 04 Jan 2017 an amino acid not produced by the body). In another embodiment, the amino acid may be a non-essential amino acid. In yet another embodiment, a label may comprise at least one essential amino acid and at least one non-essential amino acid. Generally, the choice of amino acid may be based on a variety of factors, including (1) whether the amino acid is present in at least one residue of the protein or peptide of interest; (2) whether the amino acid can quickly reach the site of protein synthesis; (3) whether the labeled amino acid affects the metabolism of the protein of interest (e.g., very large doses of leucine may affect muscle metabolism); and (4) the availability of the desired amino acid may be considered (i.e., some amino acids are much more expensive or harder to manufacture than others).
[0013] In some embodiments, a label may comprise at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, at least ten, at least eleven, at least twelve, at least thirteen, at least fourteen, at least fifteen, at least sixteen, at least seventeen, at least eighteen, at least nineteen, at least twenty, or more than twenty different kinds of labeled amino acids.
[0014] Amino acids may be labeled using any method known in the art, as long as the amino acid may be incorporated into Αβ and allows the detection of the turnover of Αβ in the blood. Labels may be radioactive or non-radioactive. For instance, in one embodiment, an amino acid may be labeled with a stable non-radioactive isotope. Non-limiting examples may include 2H, 13C, 15N, 17O, 180,33S, 34S, or 36S. Additionally, it is recognized that a number of other stable isotopes that change the mass of an atom by more or less neutrons than is seen in the prevalent native form would also be effective. In another embodiment, an amino acid may be labeled with more than one label (for instance, 13C and 15N).
[0015] In one embodiment, 13C6-phenylalanine, which contains six 13C atoms, may be used to label Αβ. In an exemplary embodiment, 13C6-leucine may be used to label Αβ. In yet another embodiment, a combination of a stable nonradioactive isotope and an amino acid listed in Table A may be used to label Αβ.
WO 2011/149947
PCT/US2011/037754
2017200029 04 Jan 2017 [0016] There are numerous commercial sources of labeled amino acids. Generally, the labeled amino acids may be produced either biologically or synthetically. Biologically produced amino acids may be obtained from an organism (e.g., kelp/seaweed) grown in an enriched mixture of 13C, 15N, or other isotope that is incorporated into amino acids as the organism produces proteins. The amino acids are then separated and purified. Alternatively, amino acids may be made with known synthetic chemical processes.
Table A
| fit | alanine |
| alanine | |
| iaN | alanine |
| 1ZO and/or iaO | alanine |
| aaS and/or J4S and/or aBS | alanine |
| arginine | |
| arginine | |
| iaN | arginine |
| 1ZO and/or iaO | arginine |
| JJS and/or J4S and/or JbS | arginine |
| Ή | asparagine |
| asparagine | |
| iaN | asparagine |
| 1ZO and/or iaO | asparagine |
| JJS and/or J4S and/or JbS | asparagine |
| Ή | aspartic acid |
| aspartic acid | |
| iaN | aspartic acid |
| 1ZO and/or iaO | aspartic acid |
| JJS and/or J4S and/or JbS | aspartic acid |
| cysteine | |
| cysteine | |
| iaN | cysteine |
| 1ZO and/or iaO | cysteine |
WO 2011/149947
PCT/US2011/037754
2017200029 04 Jan 2017
| JJS and/or J4S and/or JbS | cysteine |
| ft | glutamic acid |
| glutamic acid | |
| iaN | glutamic acid |
| 1ZO and/or iaO | glutamic acid |
| JJS and/or J4S and/or JbS | glutamic acid |
| ft | glutamine |
| glutamine | |
| iaN | glutamine |
| 1ZO and/or iaO | glutamine |
| JJS and/or J4S and/or JbS | glutamine |
| ft | glycine |
| glycine | |
| iaN | glycine |
| 1ZO and/or iaO | glycine |
| JJS and/or J4S and/or JbS | glycine |
| ft | histidine |
| histidine | |
| iaN | histidine |
| 1ZO and/or iaO | histidine |
| and/or 4S and/or bS | histidine |
| ft | isoleucine |
| isoleucine | |
| iaN | isoleucine |
| 1ZO and/or iaO | isoleucine |
| aaS and/or 4S and/or bS | isoleucine |
| ft | leucine |
| leucine | |
| iaN | leucine |
| 1ZO and/or iaO | leucine |
| S and/or 4S and/or bS | leucine |
| ft | lysine |
| lysine | |
| iaN | lysine |
| 1ZO and/or iaO | lysine |
WO 2011/149947
PCT/US2011/037754
2017200029 04 Jan 2017
| JJS and/or J4S and/or JbS | lysine |
| methionine | |
| methionine | |
| iaN | methionine |
| 1ZO and/or iaO | methionine |
| JJS and/or J4S and/or JbS | methionine |
| Ή | phenylalanine |
| phenylalanine | |
| iaN | phenylalanine |
| 1ZO and/or iaO | phenylalanine |
| JJS and/or J4S and/or JbS | phenylalanine |
| Ή | proline |
| proline | |
| iaN | proline |
| 1ZO and/or iaO | proline |
| JJS and/or J4S and/or JbS | proline |
| serine | |
| serine | |
| iaN | serine |
| 1ZO and/or iaO | serine |
| aaS and/or a4S and/or abS | serine |
| threonine | |
| threonine | |
| iaN | threonine |
| 1ZO and/or iaO | threonine |
| aaS and/or a4S and/or abS | threonine |
| Ή | tryptophan |
| tryptophan | |
| iaN | tryptophan |
| 1ZO and/or iaO | tryptophan |
| JJS and/or J4S and/or JbS | tryptophan |
| Ή | tyrosine |
| tyrosine | |
| iaN | tyrosine |
| 1ZO and/or iaO | tyrosine |
WO 2011/149947
PCT/US2011/037754
2017200029 04 Jan 2017
| JJS and/or J4S and/or JbS | tyrosine |
| valine | |
| valine | |
| lbN | valine |
| 1ZO and/or iaO | valine |
| JJS and/or J4S and/or JbS | valine |
ii. methods of administration [0017] Suitable methods of administering a label may include any method that allows the measurement of the turnover of Αβ in blood. In one embodiment, a label may be administered parenterally, e.g. intravenously, intraarterially, subcutaneously, intraperitoneally, or intramuscularly. In yet another embodiment, a label may be administered orally.
[0018] A label may be administered in several different ways, depending in part, on the type of label. In one embodiment, a label may be administered as an infusion over time. For instance, a label may be administered via an infusion for about 1,2,3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21,22, 23, 23, 25, 26, 27, 28, 29, 30, 31,32, 33, 34, 35, 36, 37, 38, 39,
40, 41,42, 43, 44, 45, 46, 47, 48, 49, 50, 51,52, 53, 54, 55, 56, 57, 58, 59, 60,
61,62, 63, 64, 65, 66, 67, 68, 69, 70, 71,72, 73, 74, 75, 76, 77, 78, 79, 80, 81,
82, 83, 84, 85, 86, 87, 88, 89, 90, 91,92, 93, 94, 95, 96, 97, 98, 99, 100, 101,
102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, or 120 minutes. Alternatively, a label may be administered via an infusion for about 2, 2.25, 2.5, 2.75, 3, 3.25, 3.5, 3.75, 4, 4.25, 4.5, 4.75, 5, 5.25,
5.5, 5.75, 6, 6.25, 6.5, 6.75, 7, 7.25, 7.5, 7.75, 8, 8.25, 8.5, 8.75, 9, 9.25, 9.5,
9.75, 10, 10.25, 10.5, 10.75, 11, 11.25, 11.5, 11.75, 12, 12.25, 12.5, or 12.75 hours. In still other embodiments, a label may be administered as an infusion for more than 13 hours. In an exemplary embodiment, the label may be administered as an IV infusion.
WO 2011/149947
PCT/US2011/037754
2017200029 04 Jan 2017 [0019] A label may also be administered in one or more boluses. For instance, a label may be administered in one bolus, two boluses, three boluses, four boluses, five boluses, or more than five boluses. Generally speaking, a bolus is a discrete administration for a duration of no longer than about 1 hour. In one embodiment, a bolus is administered in 1,2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21,22, 23, 23, 25, 26, 27, 28, 29, 30, 31,32, 33, 34, 35,
36, 37, 38, 39, 40, 41,42, 43, 44, 45, 46, 47, 48, 49, 50, 51,52, 53, 54, 55, 56,
57, 58, 59, 60, 61,62, 63, 64, 65, 66, 67, 68, 69, 70, 71,72, 73, 74, 75, 76, 77,
78, 79, 80, 81,82, 83, 84, 85, 86, 87, 88, 89, 90, 91,92, 93, 94, 95, 96, 97, 98,
99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, or 120 seconds. In another embodiment, a bolus is administered in 1,2, 3, 4, 5, 6,7,8,9,10,11,12,13,14,15,16,17,18,19, 20,
21,22, 23, 23, 25, 26, 27, 28, 29, 30, 31,32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51,52, 53, 54, 55, 56, 57, 58, 59, or 60 minutes. The time between boluses may be seconds, minutes, hours, or days.
For instance, the time between boluses may be about 1,2,3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21,22, 23, 23, 25, 26, 27, 28, 29, 30, 31,
32, 33, 34, 35, 36, 37, 38, 39, 40, 41,42, 43, 44, 45, 46, 47, 48, 49, 50, 51,52,
53, 54, 55, 56, 57, 58, 59, 60, 61,62, 63, 64, 65, 66, 67, 68, 69, 70, 71,72, 73,
74, 75, 76, 77, 78, 79, 80, 81,82, 83, 84, 85, 86, 87, 88, 89, 90, 91,92, 93, 94,
95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, or 120 sec. Alternatively, the time between boluses may be about 1,2,3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21,22, 23, 23, 25, 26, 27, 28, 29, 30, 31,32, 33, 34, 35, 36, 37,
38, 39, 40, 41,42, 43, 44, 45, 46, 47, 48, 49, 50, 51,52, 53, 54, 55, 56, 57, 58,
59, 60, 61,62, 63, 64, 65, 66, 67, 68, 69, 70, 71,72, 73, 74, 75, 76, 77, 78, 79,
80, 81,82, 83, 84, 85, 86, 87, 88, 89, 90, 91,92, 93, 94, 95, 96, 97, 98, 99, 100,
101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116,
117, 118, 119, or 120 minutes. In another alternative, the time between boluses may be about 1, 1.25, 1.5, 1.75, 2, 2.25, 2.5, 2.75, 3, 3.25, 3.5, 3.75, 4, 4.25, 4.5,
WO 2011/149947
PCT/US2011/037754
2017200029 04 Jan 2017
4.75, 5, 5.25, 5.5, 5.75, 6, 6.25, 6.5, 6.75, 7, 7.25, 7.5, 7.75, 8, 8.25, 8.5, 8.75, 9,
9.25, 9.5, 9.75, 10, 10.25, 10.5, 10.75, 11, 11.25, 11.5, 11.75, 12, 12.25, 12.5,
12.75, 13, 13.25, 13.5, 13.75, 14, 14.25, 14.5,14.75, 15, 15.25, 15.5, 15.75, 16,
16.25, 16.5, 16.75, 17, 17.25, 17.5, 17.75, 18, 18.25, 18.5, 18.75, 19, 19.25,
19.5, 19.75, 20, 20.25, 20.5, 20.75, 21,21.25, 21.5, 21.75, 22, 22.25, 22.5,
22.75, 23, 23.25, 23.5, 23.75, 24, 24.25, 24.5, 24.75, 25, 25.25, 25.5, 25.75, 26,
26.25, 26.5, 26.75, 27, 27.25, 27.5, 27.75, 28, 28.25, 28.5, 28.75, 29, 29.25,
29.5, 29.75, 30, or more than 30 hours.
[0020] In an exemplary embodiment, the label may be administered in at least one oral or IV bolus. In certain embodiments, a label may be administered via a combination of a bolus and an infusion. For instance, a subject may be administered a bolus of label, followed by an infusion of label.
[0021 ] Those of skill in the art will appreciate that the amount (or dose) of the label can and will vary, depending in part on the route of administration and the label used. Generally speaking, the amount should be sufficient to allow the measurement of Αβ turnover in blood. In some embodiments, if the label is administered via infusion, the amount may be between about 0.01 mg/kg/hr to about 4.5 mg/kg/hr. For instance, the amount may be about 0.001,0.005, 0.01, 0.15, 0.2, 0.25, 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.25, 2.5, 2.75, 3, 3.25, 3.5, 3.75, 4, 4.25, or 4.5 mg/kg/hr. In other embodiments, if the label is administered via bolus, the amount may be between about 0.01 g to about 8 g. For example, the amount may be 0.001,0.005, 0.01,0.02, 0.03, 0.04, 0.05, 0.06, 0.07, 0.08, 0.09, 0.1,0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2, 2.1,2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, 3, 3.1,3.2, 3.3, 3.4, 3.5, 3.6, 3.7, 3.8, 3.9, 4, 4.1,4.2, 4.3, 4.4, 4.5, 4.6, 4.7, 4.8, 4.9, 5, 5.1,5.2, 5.3, 5.4, 5.5, 5.6, 5.7, 5.8, 5.9, 6, 7 or 8 g.
(b) collecting a blood sample [0022] A method of the invention comprises, in part, collecting at least one blood sample from a subject. The blood sample typically contains labeled
WO 2011/149947
PCT/US2011/037754
2017200029 04 Jan 2017
Αβ. The sample may also contain unlabeled Αβ. As used herein, “blood” refers to whole blood, plasma, or serum. Methods of collecting a blood sample are well known in the art. In an exemplary embodiment, venipuncture, with or without a catheter, may be used to collect a blood sample. In another exemplary embodiment, a finger stick, or the equivalent, may be used to collect a blood sample.
[0023] Generally speaking a blood sample is collected after the administration of a label, described in section I (a) above. A skilled artisan will appreciate that the time a blood sample is collected (after administration of a label) can and will vary depending on the label and the method of administering the label. In one embodiment, a blood sample is collected between about 1 min and about 48 hours after administration of a label. For instance, a blood sample may be collected between about 1 min and 48 hours, between about 1 min and 10 hours, or between about 1 min and 30 hours. In another embodiment, a blood sample may be collected between about 10 min and about 24 hours after administration of a label. In yet another embodiment, a blood sample may be collected between about 10 min and about 10 hours after administration of a label. For instance, a blood sample may be collected between about 15 min and 8 hours, between about 15 min and 6 hours, between about 15 min and 4 hours, between about 30 min and 5 hours, between about 1 hour and 5 hours, between about 1 hour and 4 hours, between about 2 hours and 4 hours, or between about 2 hours and 6 hours. In still another embodiment, a blood sample may be collected between about 10 hours and about 20 hours after administration of a label. For example, a blood sample may be collected between about 12 hours and 20 hours, between about 14 hours and 20 hours, between about 16 hours and 20 hours, or about 18 hours and 20 hours. In yet still another embodiment, a blood sample may be collected between about 20 hours and about 30 hours after administration of a label. For instance, a blood sample may be collected between about 22 hours and 28 hours or between about 24 hours and 28 hours. In an alternative embodiment, a blood sample may be collected after 30 hours after
WO 2011/149947
PCT/US2011/037754
2017200029 04 Jan 2017 administration of a label. For instance, a blood sample may be collected after 30, 32, 34, 36, 38, 40, 42, 44, 46, 48 or greater than 48 hours after administration of a label.
[0024] In some embodiments, a blood sample may be collected after about 1,2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21,22, 23, 23, 25, 26, 27, 28, 29, 30, 31,32, 33, 34, 35, 36, 37, 38, 39, 40, 41,42, 43, 44,
45, 46, 47, 48, 49, 50, 51,52, 53, 54, 55, 56, 57, 58, 59, 60, 61,62, 63, 64, 65,
66, 67, 68, 69, 70, 71,72, 73, 74, 75, 76, 77, 78, 79, 80, 81,82, 83, 84, 85, 86,
87, 88, 89, 90, 91,92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105,
106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, or 120 sec after administration of a label. In other embodiments, a blood sample may be collected after about 1,2,3, 4, 5, 6,7,8,9,10,11,12,13,14,15,16,17,18,19, 20, 21,22, 23, 23, 25, 26, 27, 28, 29, 30, 31,32, 33, 34, 35, 36, 37, 38, 39, 40,
41,42, 43, 44, 45, 46, 47, 48, 49, 50, 51,52, 53, 54, 55, 56, 57, 58, 59, 60, 61,
62, 63, 64, 65, 66, 67, 68, 69, 70, 71,72, 73, 74, 75, 76, 77, 78, 79, 80, 81,82,
83, 84, 85, 86, 87, 88, 89, 90, 91,92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102,
103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118,
119, or 120 minutes after administration of a label. In certain embodiments, a blood sample may be collected after about 1, 1.25, 1.5, 1.75, 2, 2.25, 2.5, 2.75,
3, 3.25, 3.5, 3.75, 4, 4.25, 4.5, 4.75, 5, 5.25, 5.5, 5.75, 6, 6.25, 6.5, 6.75, 7, 7.25,
7.5, 7.75, 8, 8.25, 8.5, 8.75, 9, 9.25, 9.5, 9.75, 10, 10.25, 10.5, 10.75, 11, 11.25,
11.5, 11.75, 12, 12.25, 12.5, 12.75, 13, 13.25, 13.5, 13.75, 14, 14.25, 14.5,14.75, 15, 15.25, 15.5, 15.75, 16, 16.25, 16.5, 16.75, 17, 17.25, 17.5, 17.75, 18, 18.25,
18.5, 18.75, 19, 19.25, 19.5, 19.75, 20, 20.25, 20.5, 20.75, 21,21.25, 21.5,
21.75, 22, 22.25, 22.5, 22.75, 23, 23.25, 23.5, 23.75, 24, 24.25, 24.5, 24.75, 25,
25.25, 25.5, 25.75, 26, 26.25, 26.5, 26.75, 27, 27.25, 27.5, 27.75, 28, 28.25,
28.5, 28.75, 29, 29.25, 29.5, 29.75, or 30 hours after administration of a label.
[0025] In exemplary embodiments, if the label is administered intravenously for about 9 hours, a blood sample may be collect between about one hour and about 15 hours, between about 5 hours and about 13 hours, or
WO 2011/149947
PCT/US2011/037754
2017200029 04 Jan 2017 between about 8 hours and about ten hours after administration of the label. In one exemplary embodiment, if the label is administered intravenously, a blood sample may be collected about nine hours after administration of the label. In other exemplary embodiments, if the label is administered orally, a blood sample may be collected between about 30 min and about 5 hours or between about 1 hour and four hours after administration of the label. In a certain exemplary embodiment, if the label is administered orally, a blood sample may be collected about three hours after administration of the label.
[0026] More than one blood sample may be collected from a subject. For instance, 1,2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 23, 25, 26, 27, 28, 29, 30, 31,32, 33, 34, 35, 36, 37, 38, 39, 40, or more than 40 blood samples may be collected from a subject. The time between samples may be seconds, minutes, hours, or days. For instance, the time between samples may be about 1,2,3, 4, 5, 6,7,8,9,10,11,12,13,14,15,16, 17, 18, 19, 20, 21,22, 23, 23, 25, 26, 27, 28, 29, 30, 31,32, 33, 34, 35, 36, 37,
38, 39, 40, 41,42, 43, 44, 45, 46, 47, 48, 49, 50, 51,52, 53, 54, 55, 56, 57, 58,
59, 60, 61,62, 63, 64, 65, 66, 67, 68, 69, 70, 71,72, 73, 74, 75, 76, 77, 78, 79,
80, 81,82, 83, 84, 85, 86, 87, 88, 89, 90, 91,92, 93, 94, 95, 96, 97, 98, 99, 100,
101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116,
117, 118, 119, or 120 sec. Alternatively, the time between samples may be about 1,2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21,22, 23, 23,
25, 26, 27, 28, 29, 30, 31,32, 33, 34, 35, 36, 37, 38, 39, 40, 41,42, 43, 44, 45,
46, 47, 48, 49, 50, 51,52, 53, 54, 55, 56, 57, 58, 59, 60, 61,62, 63, 64, 65, 66,
67, 68, 69, 70, 71,72, 73, 74, 75, 76, 77, 78, 79, 80, 81,82, 83, 84, 85, 86, 87,
88, 89, 90, 91,92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, or 120 minutes. In another alternative, the time between samples may be about 1, 1.25, 1.5, 1.75, 2, 2.25, 2.5, 2.75, 3, 3.25, 3.5, 3.75, 4, 4.25, 4.5, 4.75, 5, 5.25, 5.5, 5.75, 6, 6.25,
6.5, 6.75, 7, 7.25, 7.5, 7.75, 8, 8.25, 8.5, 8.75, 9, 9.25, 9.5, 9.75, 10, 10.25, 10.5,
10.75, 11, 11.25, 11.5, 11.75, 12, 12.25, 12.5, 12.75, 13, 13.25, 13.5, 13.75, 14,
WO 2011/149947
PCT/US2011/037754
2017200029 04 Jan 2017
14.25, 14.5,14.75, 15, 15.25, 15.5, 15.75, 16, 16.25, 16.5, 16.75, 17, 17.25, 17.5,
17.75, 18, 18.25, 18.5, 18.75, 19, 19.25, 19.5, 19.75, 20, 20.25, 20.5, 20.75, 21,
21.25, 21.5, 21.75, 22, 22.25, 22.5, 22.75, 23, 23.25, 23.5, 23.75, 24, 24.25,
24.5, 24.75, 25, 25.25, 25.5, 25.75, 26, 26.25, 26.5, 26.75, 27, 27.25, 27.5,
27.75, 28, 28.25, 28.5, 28.75, 29, 29.25, 29.5, 29.75, 30, or more than 30 hours.
[0027] The blood sample should typically be large enough to allow the measurement of Αβ turnover. More than one sample may be pooled for a particular time point. In one embodiment, a blood sample may be about 50μΙ_ to about 3000μΙ_. For instance, a blood sample may be about 50, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1000, 1050, 1100, 1150, 1200, 1250, 1300, 1350, 1400, 1450, 1500, 1550, 1600, 1650,
1700, 1750, 1800, 1850, 1900, 1950, 2000, 2050, 2100, 2150, 2200, 2250, 2300,
2350, 2400, 2450, 2500, 2550, 2600, 2650, 2700, 2750, 2800, 2850, 2900, 2950, or 3000 μΙ_. In other embodiments, a blood sample may be more than 3000μΙ_.
(c) analyzing the sample to determine the turnover of Αβ [0028] A method of the invention, comprises, in part, analyzing the sample to determine the turnover of Αβ in blood. Generally speaking, analyzing the sample encompasses (a) detecting and quantifying labeled and unlabeled Αβ in a blood sample and (b) deriving the turnover of Αβ from the quantity of labeled and unlabeled Αβ in the blood sample. Each step is discussed in more detail below.
/'. detecting and quantifying labeled and unlabeled Αβ in a blood sample [0029] The method of detecting and quantifying labeled and unlabeled
Αβ in a blood sample can and will vary. For instance, detection methods will vary with the type of label used (e.g. radioactive or non-radioactive). In one embodiment, if a non-radioactive label is used, the detection method should be sensitive enough to detect changes in mass of the labeled protein with respect to the unlabeled protein. For instance, labeled and unlabeled Αβ may be detected
WO 2011/149947
PCT/US2011/037754
2017200029 04 Jan 2017 with mass spectrometry. In one embodiment, the mass spectrometry protocol outlined in the Examples is used.
[0030] Additional techniques may be used to separate the labeled and unlabeled Αβ from other blood components, or to concentrate the labeled and unlabeled Αβ in a sample. For instance, labeled and unlabeled Αβ may be immunoprecipitated from a blood sample. Protocols for immunoprecipitations are known in the art. In one embodiment, the immunoprecipitation antibody may be attached to a solid support, such as a bead or resin. In another embodiment, the immunoprecipitation protocol detailed in the Examples may be used. Other methods of separating or concentrating Αβ may include chromatography. In particular, techniques linking a chromatographic step with a mass spectrometry step may be used.
[0031] To aid in detection and quantification of labeled and unlabeled Αβ, the Αβ may be divided into smaller peptides. For instance, Αβ may be digested with a protease to create several small peptides. In one embodiment, trypsin is used to digest Αβ.
[0032] Generally speaking, the method of detecting labeled and unlabeled Αβ may also be used to quantify the amount of labeled and unlabeled Αβ. In some embodiments, quantification encompasses determining the ratio between labeled and unlabeled Αβ.
ii. deriving the turnover of Αβ [0033] From the detection and quantification step outlined above, the turnover of Αβ may be derived. As used herein, “turnover” refers in one embodiment to the rate of labeled Αβ production, the rate of labeled Αβ clearance, or a combination of both. In another embodiment, “turnover” refers to the half-life of Αβ in blood. In still another embodiment, “turnover” refers to the product of the percent labeled Αβ and the absolute quantitation value of Αβ. For instance, “turnover” may refer to the product of the percent labeled Αβ42 to the absolute quantitation value of Αβ42.
WO 2011/149947
PCT/US2011/037754
2017200029 04 Jan 2017 [0034] Turnover may be calculated, in part, from the change over time in labeled, unlabeled or ratio of labeled to unlabeled Αβ. In other embodiments, turnover may be determined from the peak of labeled Αβ. In still other embodiments, fractional synthesis rate, fractional clearance rate, absolute synthesis rate, absolute clearance rate, half-life, decay rate, or compartmental modeling may be used to determine turnover. In each embodiment, turnover may be calculated using the in vivo labeled Αβ, in vivo unlabled Αβ, the ex vivo internal standard (absolute quantitation), or a combination thereof.
II. Kit [0035] An alternative embodiment of the invention encompasses a kit. The kit typically comprises a solution of at least one labeled amino acid. In one embodiment, the solution is a shake or drink that may be consumed orally. The kit also contains instructions for administering the labeled amino acid solution and subsequently collecting at least one blood sample. The kit may also contain a container and/or paraphernalia for collecting and storing the blood sample. Additionally, the kit may contain an internal standard to ensure that that blood sample is of adequate quality to be analyzed for Αβ turnover and for absolute quantitation of labeled and unlabeled Αβ.
[0036] Yet another aspect of the present application encompasses a business method. Generally speaking, the method comprises distributing a kit of the invention to either a physician or individual. After the kit is used to collect a sample from the subject following the directions included in the kit, the sample is then returned to a lab for processing using a method of the invention.
[0037] The following examples are included to demonstrate preferred embodiments of the invention. It should be appreciated by those of skill in the art that the techniques disclosed in the examples that follow represent techniques discovered by the inventors to function well in the practice of the invention. Those of skill in the art should, however, in light of the present disclosure, appreciate that many changes can be made in the specific embodiments that are disclosed
WO 2011/149947
PCT/US2011/037754
2017200029 04 Jan 2017 and still obtain a like or similar result without departing from the spirit and scope of the invention, therefore all matter set forth or shown in the accompanying drawings is to be interpreted as illustrative and not in a limiting sense.
DEFINITIONS [0038] As used herein, “bolus” refers to a discrete dosing of label. More than one bolus may be used to administer a label, but each bolus is a discrete dose. This is in contrast to an infusion, which is a continuous dose administered over time.
[0039] As used herein, “central nervous system” refers to the brain, cerebral spinal fluid, or any other tissue or fluid of the central nervous system where Αβ may be found.
[0040] As used herein, “infusion” refers to a continuous dosing of label over time. In some embodiments, the rate of the dosing may change over time.
[0041] As used herein, “metabolism” refers to any combination of the synthesis, transport, breakdown, modification, or clearance rate of a biomolecule.
[0042] As used herein, “subject” refers to any subject that has a central nervous system. In exemplary embodiments, “subject” refers to any subject that is susceptible to a disease or disorder characterized by amyloid plaques. In one exemplary embodiment, “subject” refers to an individual with AD or an individual that is at risk for AD. In another exemplary embodiment, “subject” refers to an individual that is advanced in age.
EXAMPLES [0043] The following examples illustrate various iterations of the invention.
[0044] A pioneering approach was recently developed to directly measure Αβ metabolism in the central nervous system of living humans (Bateman et. al 2006). This method requires participants be admitted to a research hospital room, and have two IV catheters and a lumbar spinal catheter
WO 2011/149947
PCT/US2011/037754
2017200029 04 Jan 2017 placed so that hourly samples of blood and cerebral-spinal fluid can be obtained. Using this method, recent studies have demonstrated that Αβ has a rapid metabolism (half-life of 8-10 hours) in the human brain and cerebral-spinal fluid (CSF).
[0045] Blood Αβ dynamics, however, are not well understood as previously there was no method to measure labeled Αβ within blood. If such a method were available, the physiology (and pathophysiology) of Αβ could be better understood as a quantitative measure of Αβ production in the brain, transport to blood and cerebral-spinal fluid, and clearance from blood. A blood labeled Αβ assay would allow for the physiology and pathophysiology of Αβ to be measured without invasive spinal catheters.
[0046] A stable isotope labeling kinetics immunoprecipitation-mass spectrometry approach was developed to measure labeled blood Αβ. This provides the ability to measure blood Αβ production, transport between compartments, and clearance rates in humans.
[0047] The half-life of blood/plasma Αβ is distinctly different than in the CNS/CSF, with a t1 /2 of 1 to 3 hours in production (FIG. 1). This contrasts with a half-life of 8 to 10 hours as measured in CSF (Bateman et. al 2006). For FIG. 1, subjects were administered a labeled amino acid (13C6 leucine; infused over 9 hours with a 10 minute primed infusion 2 mg/kg, followed by 2 mg/kg/hour for 8 hours and 50 minutes) and then blood samples were taken every hour for 0 - 15 hr, then every odd hour to hour 35, then at 36 & 48 hours. Twenty-eight samples were taken in total. The samples were stored frozen. Then, samples were thawed and a protease inhibitor cocktail was added. Samples were centrifuged and then pooled from two samples of plasma (2 mis total) at every time point. Next, Αβ was immunoprecipitated from the samples as described below:
WO 2011/149947
PCT/US2011/037754
2017200029 04 Jan 2017
Day 1:
[0048] 1. Samples thawed on ice.
[0049] 2. Add 20 μΙ of Complete Protease Inhibitors (Roche, 1 tab dissolved in 1 ml water)
| [0050] particulates. [0051] [0052] [0053] | 3. Centrifuge at 14,000 RPM at 4°C for 15 minutes to remove 4. Pool the supernatants. 5. Dilute media standards into PBS. 6. Wash HJ5.1 (Αβ specific antibody) beads twice with 1x PBS |
with 0.02% azide. Make 50% bead slurry at the end
| [0054] [0055] [0056] [0057] Αβ). [0058] | 7. Add 220 μΙ 5M guanidine hydrochloride solution. 8. Add 20 ul Tween-20 (5% in PBS for 0.05% final) 9. Add 5 ul of ISTD (Ν15- Αβ). 10. Add 30 pi antibody- beads (50% slurry enough for ~20ng 11. Incubate overnight at 4°C. |
| Day 2: [0059] [0060] only). [0061] [0062] [0063] [0064] [0065] [0066] | 12. Centrifuge beads at 4500 RPM for 5 minutes. 13. Remove supernatant into a new tube and save (plasma 14. Add 1 ml 0.5M guanidine hydrochloride solution 15. Add 10 ul of 5% for 0.05% final Tween-20. 16. Once re-suspended transfer beads to 1.5 ml tube. 17. Centrifuge beads at 4500 RPM for 5 minutes. 18. Discard supernatant. 19. Wash the beads two times with 1x AmBiC rinse. Discard the |
supernant and dry beads [0067] 20. Add 50 μΙ (bead volume) 98% formic acid (elution solution) and centrifuge beads. Remove supernatant and place in 1.5 ml tube.
WO 2011/149947
PCT/US2011/037754
2017200029 04 Jan 2017 [0068] 21. Dry the elution solution in a speedvac for 1 hour to remove formic acid (37°C).
[0069] 23.Thaw 20 pg trypsin. Add 1 ml of 25mM AmBiC solution to resuspend the trypsin to a final concentration of 20 ng/ul.
[0070] 24. Re-suspend the proteins in 10 ul solution of 25 mM AmBiC.
[0071 ] 25. Add 10 μΙ of the 20 ng/μΙ trypsin solution to the beads for digestion.
[0072] 26. Digest O/N (16 hrs) at 37°C in the incubator.
DAY 3:
[0073] 27. Perform a short spin of the samples to let condensate settle at the bottom of tube.
[0074] 28. Add 2 ul of formic acid to the digest (to precipitate proteins) [0075] 29. Mix samples.
[0076] 30. Centrifuge the tryptic digest at 14,000 RPM at 4°C for 15 minutes.
[0077] 31 .Transfer to autosampler vials then spin down samples using the speedvac and keep in the refrigerator at 4°C.
[0078] The samples were then analyzed by mass spectrometry as follows:
[0079] The amino acid sequence of Αβ 1-42 is DAEFRHDSGYEVHH QKLVFFAEDVGSNKGAIIGLMVGGVVIA (SEQ ID NO:1) and Αβ 1-40 is DAEFRHDSGYEVH HQKLVFFAEDVGSNKGAIIGLMVGGVV (SEQ ID NO:2). When it is digested with a protease like trypsin, four smaller peptides are generated as Αβ 1-5 DAEFR (SEQ ID NO:3), Αβ 6-16 HDSGYEVHHQK (SEQ ID NO:4), Αβ 17-28 LVFFAEDVGSNK (SEQ ID NO:5), and Αβ 29-42 GAIIGLMVGGVVIA (SEQ ID NO:6). Only two of these peptides are of relevance for quantitation using the SILK technology (Stable Isotope Labeling Kinetics Bateman et. al 2009) with leucine labeling because their sequence includes a
WO 2011/149947
PCT/US2011/037754
2017200029 04 Jan 2017 leucine residue that can be labeled in vivo. These peptides are Αβ 17-28 LVFFAEDVGSNK (SEQ ID N0:5), and Αβ 29-42 GAIIGLMVGGVVIA (SEQ ID N0:6), but we use only the Αβ 17-28 LVFFAEDVGSNK (SEQ ID NO:5) peptide because it represents the total amounts of Αβ in the blood and produces a higher signal. Of course, it may be useful to also quantify the c-terminal (Αβ 29-42 GAIIGLMVGGVVIA (SEQ ID NO:6) or Αβ 29-40 GAIIGLMVGGVV (SEQ ID NO:7)) or n-terminal fragments in the blood as well. In general, any amino acid label can be used, any endoprotease can be used (or none at all) to label Αβ & quantify the label in the blood.
[0080] Experiments were performed on a TSQ Vantage mass spectrometer coupled to a nanoflow ESI source and a nano-2D liquid chromatography (NanoLC-2D). The samples were maintained at a temperature of 4°C in the autosampler tray. Samples were injected onto a home-made nano column (150-mm diameter) with a pulled tip, packed to 15 cm with Ace 5 C18 AR column packing material (MAC-MOD Analytical, Chadds Ford, PA). Peptides were separated by the Nano2D-LC (Eksigent, Inc. Ultra NanoLC-2D) at a flow rate of 1 mL/ min. Solvent A was 0.1 % formic acid in water and solvent B was 0.1% formic acid in acetonitrile. The gradient was 15% B to 25% B in 10 min followed by 25% B to 95% B in 5 min, then, ramped down to 15% B in 2 min and the column re-equilibrated for 3 min while the autosampler was picking another sample for injection.
[0081] The TSQ Vantage mass spectrometer (MS) was operated in positive ion mode using a spray voltage of 1.2 kV, with optimized parameters from tuning with peptides. Data was acquired in Multiple Reaction Monitoring (MRM) mode. During this MRM experiments, the mass of the peptide was first detected in the first dimension, or as MS1. While MS1 is used to perform quantitation, the technique suffers from lack of specificity especially in very complex matrices like blood and due to the fact that many peptides have the same intact mass. The peptide ions were fragmented and detected in the mass spectrometer and this second dimension of MS fragmentation (MS2) provided
WO 2011/149947
PCT/US2011/037754
2017200029 04 Jan 2017 unique fragments. The combination of the specific precursor mass and the unique fragment ions were used to selectively monitor the peptide to be quantified. In this case, multiple fragment ions (also known as reactions) were selectively monitored to quantitate Αβ 17-28, resulting in a unique MRM experiment. Αβ 17-28 has a precursor mass (MS1) with a charge to mass ratio of 663.340 for the endogenous peptide and 666.340 for the label incorporated peptide. Three each of their fragment ions were monitored after the MS2 fragmentation. The fragment ions also known as transition ions monitored have a mass to charge ratios of 819.38, 966.45 and 1113.52. The MRM experiments are detected and plotted as single chromatographic peaks which were processed by Xcalibur, which is the instrument control software.
[0082] Figure 3 shows the difference between administering an oral (B) label versus an intravenous (A) label. For each of the isoforms tested, the labeling peak occurred between about 1 and 5 hours for oral administration and between about 5 and 10 hours for intravenous administration. Label and samples were administered and collected, respectively, as described above.
[0083] Figure 4 shows the absolute quantitation of plasma Αβ isoforms, again measured using the protocol above. Labeled N15 Amyloid-beta internal standards (ISTD) were added to the sample before processing. Samples were processed as described above.
2017200029 04 Jan 2017
Claims (11)
- The claims defining the invention are:1. An in vitro method for measuring the in vivo rate of Αβ turnover in the blood of a subject, the method comprising:(a) determining by mass spectrometry the amount of labelled Αβ, or the amount of labelled Αβ and unlabelled Αβ, in a blood sample obtained from the subject;(b) calculating the rate of Αβ clearance using the amount of labeled Αβ, or the amount of labeled Αβ and the amount of unlabeled Αβ, determined in step (a), wherein (i) the rate of Αβ clearance is calculated from the amount of labeled Αβ, or the amount of labeled Αβ and the amount of unlabeled Αβ, in a sample obtained between 10 hours and 20 hours after intravenous administration by a 9 hour infusion has begun of at least one amino acid labelled with a stable non-radioactive isotope to the subject, or (ii) the rate of Αβ clearance is calculated from the amount of labeled Αβ, or the amount of labeled Αβ and the amount of unlabeled Αβ, in a sample obtained after 4, 5, 6, 7, 8, 9, or 10 hours after oral or intravenous bolus administration of at least one amino acid labelled with a stable non-radioactive isotope to the subject.
- 2. The method of claim 1, wherein the labelled amino acid was administered orally.
- 3. The method of claim 2, wherein between about 0.05g and about 8g of amino acid labelled with a stable non-radioactive isotope was administered.
- 4. The method of claim 1, wherein the labelled amino acid was administered intravenously.
- 5. The method of claim 4, wherein the labelled amino acid was administered as an infusion at between about 0.01mg/kg/hour and about 3 mg/kg/hour.2017200029 04 Jan 2017
- 6. The method of claim 1, wherein step (a) further comprises initially isolating Αβ from the blood sample.
- 7. The method of claim 1, wherein the amount of labeled Αβ or unlabeled Αβ is selected from the group consisting of total Αβ, Αβ38, Αβ4ο, and Αβ42.
- 8. The method of claim 1, wherein Αβ turnover is calculated from at least two blood samples.
- 9. The method of claim 1, wherein the stable non-radioactive isotope is selected from the group consisting of 2H, 13C, 15N, 17O, 18O, 33S, 34S, and 36S.
- 10. The method of claim 12, wherein the stable non-radioactive isotope is 13C.
- 11. The method of claim 1, wherein the labelled amino acid is 13C6-leucine or 13C6-phenylalanine.WO 2011/149947PCT/US2011/0377541/42017200029 04 Jan 2017FIG. 1Plasma Abeta CSF AbetaHourWO 2011/149947PCT/US2011/0377542/42017200029 04 Jan 2017
1 «-· SE J s: w s: s-l w W w u 69 © •sj· 6<5 5 < « •;$ WO 2011/149947PCT/US2011/0377543/42017200029 04 Jan 2017 §ifj «S o«j aΉOΉOQCMoLL8{WPHWO 2011/149947PCT/US2011/0377544/42017200029 04 Jan 20172: <r· Tt r~ z <*» r> v* r« δ u U » ¢0 § CM £ «5 5 JZ JS Φ J2 < < < 2017200029 04 Jan 2017427199_SequenceListing_ST25 SEQUENCE LISTING <110> THE WASHINGTON UNIVERSITY BATEMAN, Randall 3.HOLTZMAN, David M.MAWUENYEGA, Kwasi G.<120> METHODS OF DETERMINING AMYLOID BETA TURNOVER IN BLOOD <130> 047563-427199 <140> PCT/US2011/037754 <141> 2011-05-24 <150> US 61/347,554 <151> 2010-05-24 <160> 7 <170> PatentIn version 3.5 <210> 1 <211> 42 <212> PRT <213> Homo sapiens <400> 1Asp Ala 1 Glu Phe Arg His Asp Ser Gly Tyr Glu Val His His Gln Lys 5 10 15 Leu Val Phe Phe Ala Glu Asp Val Gly Ser Asn Lys Gly Ala Ile Ile 20 25 30 Gly Leu Met Val Gly Gly Val Val Ile Ala 35 40 <210> 2 <211> 40 <212> PRT <213> Homo sapiens <400> 2 Asp Ala Glu Phe Arg His Asp Ser Gly Tyr Glu Val His His Gln Lys 1 5 10 15 Leu Val Phe Phe Ala Glu Asp Val Gly Ser Asn Lys Gly Ala Ile Ile Page 12017200029 04 Jan 201720 427199_SequenceListing_ST25 25 30 Gly Leu i Met Val Gly Gly Val Val 35 40 <210> 3 <211> 5 <212> PRT <213> Homo sapiens <400> 3 Asp Ala i Glu Phe Arg 1 5 <210> 4 <211> 11 <212> PRT <213> Homo sapiens <400> 4 His Asp • Ser Gly Tyr Glu Val His His Gln Lys 1 5 10 <210> 5 <211> 12 <212> PRT <213> Homo sapiens <400> 5 Leu Val . Phe Phe Ala Glu Asp Val Gly Ser Asn Lys 1 5 10 <210> 6 <211> 14 <212> PRT <213> Homo sapiens <400> 6 Gly Ala i Ile Ile Gly Leu Met Val Gly Gly Val Val Ile Ala 1 5 10 <210> 7 Page 22017200029 04 Jan 2017 <211> 12 <212> PRT <213> Homo <400> 7Gly Ala lie 1 sapiens427199_SequenceListing_ST25 lie Gly Leu Met Val Gly Gly Val Val 5 10Page 3
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2017200029A AU2017200029B2 (en) | 2010-05-24 | 2017-01-04 | Methods of determining amyloid beta turnover in blood |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US61/347,554 | 2010-05-24 | ||
| AU2011258462A AU2011258462B2 (en) | 2010-05-24 | 2011-05-24 | Methods of determining Amyloid beta turnover in blood |
| AU2015201714A AU2015201714A1 (en) | 2010-05-24 | 2015-04-02 | Methods of determining amyloid beta turnover in blood |
| AU2017200029A AU2017200029B2 (en) | 2010-05-24 | 2017-01-04 | Methods of determining amyloid beta turnover in blood |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2015201714A Division AU2015201714A1 (en) | 2010-05-24 | 2015-04-02 | Methods of determining amyloid beta turnover in blood |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2017200029A1 AU2017200029A1 (en) | 2017-02-02 |
| AU2017200029B2 true AU2017200029B2 (en) | 2018-04-19 |
Family
ID=52875988
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2015201714A Abandoned AU2015201714A1 (en) | 2010-05-24 | 2015-04-02 | Methods of determining amyloid beta turnover in blood |
| AU2017200029A Active AU2017200029B2 (en) | 2010-05-24 | 2017-01-04 | Methods of determining amyloid beta turnover in blood |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2015201714A Abandoned AU2015201714A1 (en) | 2010-05-24 | 2015-04-02 | Methods of determining amyloid beta turnover in blood |
Country Status (1)
| Country | Link |
|---|---|
| AU (2) | AU2015201714A1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021009074A1 (en) | 2019-07-12 | 2021-01-21 | Adx Neurosciences Nv | Novel markers as early predictors of alzheimer's pathology |
-
2015
- 2015-04-02 AU AU2015201714A patent/AU2015201714A1/en not_active Abandoned
-
2017
- 2017-01-04 AU AU2017200029A patent/AU2017200029B2/en active Active
Non-Patent Citations (1)
| Title |
|---|
| BATEMAN, RJ ET AL (2006) Nature Medicine 12: 856-861 * |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2015201714A1 (en) | 2015-04-23 |
| AU2017200029A1 (en) | 2017-02-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2011258462B2 (en) | Methods of determining Amyloid beta turnover in blood | |
| Kiernan et al. | Detection of novel truncated forms of human serum amyloid A protein in human plasma | |
| CA2821908C (en) | Novel biomarker and uses thereof in diagnosis, treatment of autism | |
| JP6129868B2 (en) | Methods for diagnosing Alzheimer's disease | |
| US20210096139A1 (en) | Tau kinetic measurements | |
| Robinson et al. | Release of skeletal muscle peptide fragments identifies individual proteins degraded during insulin deprivation in type 1 diabetic humans and mice | |
| AU2017200029B2 (en) | Methods of determining amyloid beta turnover in blood | |
| WO2017022562A1 (en) | Method for parallel quantification of protein variant | |
| US11740245B2 (en) | Mass spectrometry-based methods for the detection of circulating histones H3 and H2B in plasma from sepsis or septic shock (SS) patients | |
| Janzen et al. | UPLC–MS/MS analysis of C5-acylcarnitines in dried blood spots | |
| EP3637106A1 (en) | Lung cancer detection method | |
| Leytens et al. | Targeted proteomics addresses selectivity and complexity of protein degradation by autophagy | |
| Nair | Release of skeletal muscle peptide fragments identifies individual proteins 1 degraded during insulin deprivation in Type-I Diabetic humans and mice 2 3 Matthew M. Robinson1, Surendra Dasari2, Helen Karakelides1, H. Robert Bergen 3rd 3, 4 and K. Sreekumaran Nair1 5 | |
| AU2020268087A1 (en) | Methods for the fractionation of proteins |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) |